Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Τετάρτη 2 Νοεμβρίου 2016

Identification of Phenotypic Clusters of Non-steroidal Anti-inflammatory Drugs Exacerbated Respiratory Disease

Abstract

Background

Clinical presentation of non-steroidal anti-inflammatory drugs exacerbated respiratory disease (NERD) is found to be heterogeneous. This study classified phenotypic clusters to determine NERD subtypes.

Methods

We performed 2-step cluster analysis using urticaria, chronic rhinosinusitis (CRS), and atopy, in a NERD cohort comprising 302 patients. Asthma exacerbation was defined as receiving at least 1 burst of intravenous steroid treatment and/or at least 2 bursts of oral steroid use (≥ 45 mg/3days) per year. The possession rate of anti-asthmatic medications was estimated during the follow-up period.

Results

There were 4 subtypes; subtype 1 (NERD with CRS / atopy and no urticaria), subtype 2 (NERD with CRS and no urticaria / atopy), subtype 3 (NERD without CRS / urticaria), and subtype 4 (NERD with urticaria). Significant differences were found between the 4 subtypes in the female proportion, baseline FEV1%, serum total IgE level, and sputum/peripheral eosinophil count. A higher frequency of asthma exacerbations was noted in subtype 1 compared to subtype 3. The possession rates of medium to high dose ICS/LABA showed significant differences among the 4 subtypes. Metabolomic analysis showed that the 4 subtypes of NERD had a higher serum LTE4 level than those with aspirin-tolerant asthma. The patients with subtypes 1 and 3 had a higher urine LTE4 level than those with subtype 2.

Conclusion

We found 4 distinct subtypes with different clinical/biochemical findings and asthma exacerbations in a NERD cohort. These findings suggest that stratified strategies by applying subtype classification may help achieve better outcomes in the management of NERD.

This article is protected by copyright. All rights reserved.



http://ift.tt/2eUm7a8

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου